JP2022517842A - ７－シクロペンチル－２－（５－ピペラジン－１－イル－ピリジン－２－イルアミノ）－７Ｈ－ピロロ［２，３－ｄ］ピリミジン－６－カルボン酸ジメチルアミドのコハク酸塩の新規な結晶形態 - Google Patents

７－シクロペンチル－２－（５－ピペラジン－１－イル－ピリジン－２－イルアミノ）－７Ｈ－ピロロ［２，３－ｄ］ピリミジン－６－カルボン酸ジメチルアミドのコハク酸塩の新規な結晶形態 Download PDF

Info

Publication number
JP2022517842A
JP2022517842A JP2021542307A JP2021542307A JP2022517842A JP 2022517842 A JP2022517842 A JP 2022517842A JP 2021542307 A JP2021542307 A JP 2021542307A JP 2021542307 A JP2021542307 A JP 2021542307A JP 2022517842 A JP2022517842 A JP 2022517842A
Authority
JP
Japan
Prior art keywords
transformation
weight
ribociclib
salt
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021542307A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022517842A5 (https=
Inventor
グランデュリー，アルノー
パテル，ニレシュ
シェーファー，フランク
ジマーマン，ダニエル
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2022517842A publication Critical patent/JP2022517842A/ja
Publication of JP2022517842A5 publication Critical patent/JP2022517842A5/ja
Priority to JP2024074242A priority Critical patent/JP2024099797A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021542307A 2019-01-23 2020-01-23 ７－シクロペンチル－２－（５－ピペラジン－１－イル－ピリジン－２－イルアミノ）－７Ｈ－ピロロ［２，３－ｄ］ピリミジン－６－カルボン酸ジメチルアミドのコハク酸塩の新規な結晶形態 Pending JP2022517842A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024074242A JP2024099797A (ja) 2019-01-23 2024-05-01 ７－シクロペンチル－２－（５－ピペラジン－１－イル－ピリジン－２－イルアミノ）－７Ｈ－ピロロ［２，３－ｄ］ピリミジン－６－カルボン酸ジメチルアミドのコハク酸塩の新規な結晶形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962795799P 2019-01-23 2019-01-23
US62/795,799 2019-01-23
PCT/IB2020/050544 WO2020152629A1 (en) 2019-01-23 2020-01-23 New crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024074242A Division JP2024099797A (ja) 2019-01-23 2024-05-01 ７－シクロペンチル－２－（５－ピペラジン－１－イル－ピリジン－２－イルアミノ）－７Ｈ－ピロロ［２，３－ｄ］ピリミジン－６－カルボン酸ジメチルアミドのコハク酸塩の新規な結晶形態

Publications (2)

Publication Number Publication Date
JP2022517842A true JP2022517842A (ja) 2022-03-10
JP2022517842A5 JP2022517842A5 (https=) 2023-02-01

Family

ID=69467591

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021542307A Pending JP2022517842A (ja) 2019-01-23 2020-01-23 ７－シクロペンチル－２－（５－ピペラジン－１－イル－ピリジン－２－イルアミノ）－７Ｈ－ピロロ［２，３－ｄ］ピリミジン－６－カルボン酸ジメチルアミドのコハク酸塩の新規な結晶形態
JP2024074242A Pending JP2024099797A (ja) 2019-01-23 2024-05-01 ７－シクロペンチル－２－（５－ピペラジン－１－イル－ピリジン－２－イルアミノ）－７Ｈ－ピロロ［２，３－ｄ］ピリミジン－６－カルボン酸ジメチルアミドのコハク酸塩の新規な結晶形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024074242A Pending JP2024099797A (ja) 2019-01-23 2024-05-01 ７－シクロペンチル－２－（５－ピペラジン－１－イル－ピリジン－２－イルアミノ）－７Ｈ－ピロロ［２，３－ｄ］ピリミジン－６－カルボン酸ジメチルアミドのコハク酸塩の新規な結晶形態

Country Status (9)

Country Link
US (2) US12390468B2 (https=)
EP (1) EP3914353A1 (https=)
JP (2) JP2022517842A (https=)
KR (1) KR20210119444A (https=)
CN (1) CN113316471A (https=)
AU (2) AU2020211071A1 (https=)
CA (1) CA3124015A1 (https=)
IL (1) IL284510B2 (https=)
WO (1) WO2020152629A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240026T1 (hr) 2017-08-25 2024-03-29 Assia Chemical Industries Ltd Kruti oblik ribociklib sukcinata
US12390468B2 (en) 2019-01-23 2025-08-19 Novartis Ag Crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof
WO2025041004A1 (en) * 2023-08-18 2025-02-27 Alembic Pharmaceuticals Limited Polymorph of ribociclib salt
WO2025144118A1 (en) * 2023-12-27 2025-07-03 Deva Holding Novel polymorph of ribociclib dihydrochloride dihydrate and method of preparation
TW202602868A (zh) 2024-04-15 2026-01-16 瑞士商諾華公司 瑞波西利的藥物組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017039757A (ja) * 2010-11-10 2017-02-23 ノバルティス アーゲー ７−シクロペンチル−２−（５−ピペラジン−１−イル−ピリジン−２−イルアミノ）−７ｈ−ピロロ［２，３−ｄ］ピリミジン−６−カルボン酸ジメチルアミドの塩およびその製造方法
US20180282342A1 (en) * 2014-12-12 2018-10-04 Crystal Pharmatech Co., Ltd. Salt of Pyrrolo[2,3-D]pyrimidine Compound and Novel Polymorph of Salt
WO2019111160A1 (en) * 2017-12-04 2019-06-13 Sun Pharmaceutical Industries Limited Crystalline forms of ribociclib succinate

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI992711A1 (it) 1999-12-27 2001-06-27 Novartis Ag Composti organici
EA012926B1 (ru) 2001-12-20 2010-02-26 Оси Фармасьютикалз, Инк. Пирролопиримидиновые соединения, относящиеся к a-селективным антагонистам, их синтез и применение
WO2005023761A2 (en) 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
EP1781647A2 (en) 2004-07-22 2007-05-09 Astex Therapeutics Limited Thiazole and isothiazole derivatives as protein kinase inhibitors
RU2468988C2 (ru) 2005-07-22 2012-12-10 Квалкомм Инкорпорэйтэд Устройства мэмс, имеющие поддерживающие структуры, и способы их изготовления
AU2006331765A1 (en) 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3(2H)-isoquinolones and use thereof as kinase inhibitor
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
EP2818007B1 (en) 2012-02-24 2022-02-23 Nokia Technologies Oy Method and apparatus for establishing a connection with an access network based upon access network interworking information
CN105111215B (zh) * 2014-12-12 2019-06-18 苏州晶云药物科技股份有限公司 一种周期蛋白依赖性激酶抑制剂的晶型及其制备方法
US9994579B2 (en) * 2014-12-12 2018-06-12 Crystal Pharmatech Co., Ltd. Salt of pyrrolo[2,3-D]pyrimidine compound and novel polymorph of salt
EP3279201B1 (en) 2015-04-01 2019-10-23 Crystal Pharmatech Co., Ltd. Cdk inhibitor, eutectic crystal of mek inhibitor, and preparation method therefor
HRP20240026T1 (hr) 2017-08-25 2024-03-29 Assia Chemical Industries Ltd Kruti oblik ribociklib sukcinata
US11111250B2 (en) * 2017-12-22 2021-09-07 Shilpa Meicare Limited Polymorphs of Ribociclib mono succinate
US11414421B2 (en) 2018-01-20 2022-08-16 Natco Pharma Ltd Process for the preparation of ribociclib succinate and its novel crystalline forms thereof
TWI675662B (zh) 2018-05-17 2019-11-01 中化合成生技股份有限公司 瑞博西尼琥珀酸鹽（Ｒｉｂｏｃｉｃｌｉｂ ｓｕｃｃｉｎａｔｅ ｓａｌｔ）晶型Ｂ、Ｃ及Ｄ與其衍生物，以及其等之製造方法與藥物組合物
US12390468B2 (en) 2019-01-23 2025-08-19 Novartis Ag Crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017039757A (ja) * 2010-11-10 2017-02-23 ノバルティス アーゲー ７−シクロペンチル−２−（５−ピペラジン−１−イル−ピリジン−２−イルアミノ）−７ｈ−ピロロ［２，３−ｄ］ピリミジン−６−カルボン酸ジメチルアミドの塩およびその製造方法
US20180282342A1 (en) * 2014-12-12 2018-10-04 Crystal Pharmatech Co., Ltd. Salt of Pyrrolo[2,3-D]pyrimidine Compound and Novel Polymorph of Salt
WO2019111160A1 (en) * 2017-12-04 2019-06-13 Sun Pharmaceutical Industries Limited Crystalline forms of ribociclib succinate

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
平山 令明, 有機化合物結晶作製ハンドブック −原理とノウハウ−, JPN6021045084, 2008, pages 36 - 43, ISSN: 0005354879 *
芦澤 一英、他, 医薬品の多形現象と晶析の科学, JPN7015003233, 2002, pages 305 - 317, ISSN: 0005354877 *
芦澤 一英: "塩・結晶形の最適化と結晶化技術", PHARM TECH JAPAN, vol. 18, no. 10, JPN6013060608, 2002, pages 81 - 96, ISSN: 0005354880 *
長瀬 博, 最新 創薬化学 下巻, JPN6016015442, 1999, pages 347 - 354, ISSN: 0005354878 *

Also Published As

Publication number Publication date
US20250281492A1 (en) 2025-09-11
AU2023200724B2 (en) 2025-01-23
WO2020152629A1 (en) 2020-07-30
IL284510B2 (en) 2025-10-01
IL284510A (en) 2021-08-31
IL284510B1 (en) 2025-06-01
JP2024099797A (ja) 2024-07-25
AU2023200724A1 (en) 2023-03-09
EP3914353A1 (en) 2021-12-01
CN113316471A (zh) 2021-08-27
US12390468B2 (en) 2025-08-19
KR20210119444A (ko) 2021-10-05
CA3124015A1 (en) 2020-07-30
AU2020211071A1 (en) 2021-07-15
US20230042479A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
JP2022517842A (ja) ７－シクロペンチル－２－（５－ピペラジン－１－イル－ピリジン－２－イルアミノ）－７Ｈ－ピロロ［２，３－ｄ］ピリミジン－６－カルボン酸ジメチルアミドのコハク酸塩の新規な結晶形態
JP7355834B2 (ja) 固体形態のｆｇｆｒ阻害剤化合物およびその製造方法
JP6918824B2 (ja) ２−［（２Ｓ）−１−アザビシクロ［２．２．２］オクタ−２−イル］−６−（３−メチル−１Ｈ−ピラゾール−４−イル）チエノ［３，２−ｄ］ピリミジン−４（３Ｈ）−オン半水和物の結晶形
CA2761256C (en) Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
JP2020128392A (ja) ゲムシタビンリン酸ジアステレオ異性体を分離する方法
JP2018520205A (ja) レンバチニブメシル酸塩の新規結晶形及びその製造方法
TWI705060B (zh) 一種ｍｅｋ激酶抑制劑的對甲苯磺酸鹽、其結晶形式及製備方法
TWI745289B (zh) 一種週期素依賴性蛋白激酶抑制劑的結晶形式及其製備方法
JP2018503634A (ja) サイクリン依存性タンパク質キナーゼインヒビターのヒドロキシエチルスルホン酸塩、その結晶形およびその製造方法
CN115433246A (zh) 葡萄糖胺衍生物的晶型、制备方法及用途
US9884856B2 (en) Crystal form of Dabrafenib mesylate and preparation method thereof
KR20220016949A (ko) Cdk9 억제제의 결정다형 및 이의 제조방법과 용도
JP2024530315A (ja) Ｂｃｌ－２阻害剤の固体形態、それらの調製方法及び使用方法
IL279579B (en) Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof
US11160806B2 (en) Salt of N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino) piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, its preparation, and formulations containing it
RU2857779C2 (ru) Новые кристаллические формы сукцинатной соли диметиламида 7-циклопентил-2-(5-пиперазин-1-илпиридин-2-иламино)-7h-пирроло[2,3-d]пиримидин-6-карбоновой кислоты
CN113840605B (zh) N-(5-((4-乙基哌嗪-1-基)甲基)吡啶-2-基)-5-氟-4-(3-异丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺盐酸盐的结晶形式及其用途
CN105777656A (zh) 萘普替尼对甲苯磺酸盐的β晶型及制备方法和含有其的药物组合物
TWI846516B (zh) Cdk9抑制劑的多晶型物及其製法和用途
WO2025223554A1 (zh) 一种嘧啶并氮杂环类化合物的晶型及其制备方法及应用
TW202440125A (zh) 水解磷脂酸合成脢抑制劑化合物的新穎晶形
WO2026086730A1 (zh) 恩美他唑巴坦的晶型及其制备方法
WO2026067446A1 (zh) 一种大稠环化合物的盐、多晶型物及其应用
EP4714947A1 (en) Crystal form of pyrimido azacyclo compound, and preparation method therefor and use thereof
EA043251B1 (ru) Кристаллическая форма соединения для ингибирования активности cdk4/6 и ее применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240625